



PTO/SB/08A (10-96)

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1

of 2

Complete if Known

Application Number	09/241,595
Filing Date	February 2, 1999
First Named Inventor	REIMANN et al.
Group Art Unit	1632
Examiner Name	Anne M. S. Wehbe
Attorney Docket Number	REIMANN=1

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Number			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD- YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number	Kind Code ⁵ (if known)				
	AA	PCT	WO 98/52962		CAULFIELD	11-26-1998		
	AB	EP	0 326 109 A2		NEURATH	08-02-1989		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
	AC	QU et al., Humoral immune response enhanced by immunization with anti-HBs and HbsAg complex plus DNA vaccine, <u>Chemical Abstracts</u> , page 539
	AD	DAVIS et al., CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant Hepatitis B surface antigen, <u>The Journal of Immunology</u> , 160:870-876 (1998)
	AE	SCHIRMBECK et al., Nucleic acid vaccination primes hepatitis B virus surface antigen-specific cytotoxic T lymphocytes in nonresponder mice, <u>Journal of Virology</u> , 59:29-5934 (1995)
	AF	SCHIRMBECK et al., Enhancing the immunogenicity of exogenous Hepatitis B surface antigen-based vaccines for MHC-O-restricted T cells, <u>Biol. Chem.</u> , 380:285-291 (1999)
	AG	PUZO, The carbohydrate- and lipid- containing cell wall of mycobacteria, phenolic glycolipids: structure and immunological properties, <u>Microbiology</u> , 17:305-327
	AH	YAMAMOTO et al., Ability of oligonucleotides with certain palindromes to induce interferon production and augment natural killer cell activity is associated with their base length, <u>Antisense Research and Development</u> , 4:119-122 (1994)

Examiner
SignatureDate
Considered

11/22/04

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

SEP 02 2003

RECEIVED



PTO/SB/57 (10/96)

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2

of 2

Complete If Known

Application Number	09/241,595
Filing Date	February 2, 1999
First Named Inventor	REIMANN et al.
Group Art Unit	1632
Examiner Name	Anne M. S. Wehbe
Attorney Docket Number	REIMANN=1

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
AI		FELGNER et al., Asymmetric incorporation of trisialoganglioside into dipalmitoylphosphatidylcholine vesicles, <u>Biochemistry</u> , 20:2168-2172 (1981)	
AJ		WONG et al., Glycolipid transfer protein from bovine brain, <u>Biochemistry</u> , 23:6498-6505 (1984)	
AK		WOOLDRIDGE et al., Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma, <u>Blood</u> , 89(8):2994-2998 (1997)	
AL		NGUYEN et al., Contrasting effects of T cell growth factors on T cell responses to melanoma <i>in vitro</i> , <u>Cancer Immunol. Immunother.</u> , 43:345-354 (1997)	
AM		WEINER et al., Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization, <u>Proc. Natl. Acad. Sci. USA</u> , 94:10833-10837 (1997)	
AN		LOWRY et al., Protein measurement with the folin phenol reagent, <u>Department of Pharmacology</u> , 265-275 (1951)	
AO		YAMAMOTO et al., Unique palindromic sequences in synthetic oligonucleotides are required to induce INF and augment INF-mediated natural killer activity, <u>The Journal of Immunology</u> , 148:4072-4076 (1992)	
AP		GEISLER et al., Enhancement of cellular and humoral immune responses to Hepatitis C virus core protein using DNA-based vaccines augmented with cytokine-expressing plasmids, <u>The Journal of Immunology</u> , 1231-1237 (1997)	
AQ		YACHI et al., Distribution of liposomes containing mannobiose esters of fatty acid in rats, <u>J. Microencapsulation</u> , 12(4):377-388 (1995)	
AR		PERIN et al., Evaluation of possible interference of anti-inflammatory drugs upon scintigraphic imaging with macrophage targeting 99mTc-J001X: effects of methylprednisolone, dexamethasone, indomethacin and methotrexate, <u>Nucl. Med. Biol.</u> , 21(8):1093-1100 (1994)	
AS		TALMON, Transmission electron microscopy of complex fluids: The state of the art, <u>Ber. Bunsenges. Phys. Chem.</u> , 100:364-372 (1996)	
AT		DELPHEYROUX et al., A poliovirus neutralization epitope expressed on hybrid Hepatitis B surface antigen particles, <u>Science</u> , 233:472-475 (1986)	

Examiner
SignatureDate
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449A/PTO

(use as many sheets as necessary)

Sheet	1
-------	---

of	1
----	---

Complete if Known

Application Number	09/241,595
Filing Date	February 2, 1999
First Named Inventor	REIMANN et al.
Group Art Unit	1632
Examiner Name	Anne M. S. Wehbe
Attorney Docket Number	REIMANN=1

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

[illegible]

Examiner
Signature

Date
Considered

1/22/04

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.